TAS-102 plus apatinib for advanced stomach cancer
Part of Cancer clinical trials.
This trial tests a combination of two oral drugs, TAS-102 and apatinib, as a third-line treatment for advanced stomach cancer. It aims to see if this combination can help control the cancer when other treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach cancer that has been confirmed by a biopsy.
- Your cancer is advanced – it cannot be removed with surgery, or it has come back or spread to other parts of your body.
- You are between 18 and 75 years old.
- You have already had two previous treatments for your cancer that did not work or stopped working.
- You have at least one tumor that can be measured on a scan.
- Your blood counts and liver and kidney function are within certain limits, and you are not pregnant (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (PD1/TGFβ), another targeted drug (SHR2554 or apatinib), and chemotherapy for people who have not yet been treated for advanced stomach cancer. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of two drugs for advanced stomach, gastroesophageal junction, or colorectal cancer. The drugs work in different ways to attack cancer cells and may help slow down the disease.
This trial tests a pill called apatinib as a first treatment for older adults with advanced stomach or gastroesophageal junction cancer. It might help if you cannot or do not want to have chemotherapy.
This trial studies whether combining camrelizumab (an immunotherapy) and apatinib (a targeted pill) can control advanced, unresectable stomach or gastroesophageal junction cancer that has grown after first treatment. It also looks at how safe the combination is.
This trial tests a new combination of three drugs for stomach cancer that has progressed after initial immunotherapy. It aims to see if this combo can shrink tumors or slow cancer growth, potentially offering a new option for patients like you.
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
Hear when a new Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.